Validations Queue
64,690 candidate doc → node links pending adjudication. Each was auto-generated by cosine similarity ≥ 0.55 between document and prediction embeddings (bge-base-en-v1.5, 768-dim). Showing page 31 of 54, 50 rows by similarity. Adjudicating updates doc_node_links.reviewed=true with the chosen polarity, writes per-link rows to audit_log, and removes the row from this queue. Phase 4 inference will use confirmed corroborates/contradicts links as Bayesian evidence.
Pending (total)
64,690
Reviewed
13
Filtered
2,655
page 31 / 54
Showing on page
50
Filters
URL params control source + min-similarity threshold
Bulk auto-confirm by similarity threshold
Confirm or label (corroborates / contradicts) all unreviewed links above a similarity threshold in one transaction. Each affected row writes a per-link audit_log entry. Capped at 1,000 links per call. Use Preview first.
Source0 selected · 0 visible
Bulk action
| Sim | Doc | Source | Pred | Domain | Prior | |
|---|---|---|---|---|---|---|
| 0.58 | FDA ANDA218148: ATROPINE SULFATE (ATROPINE SULFATE) — MANKIND PHARMA | fda 2026-05-07 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.58 | FDA BLA761195: VYVGART (EFGARTIGIMOD ALFA) — ARGENX BV | fda 2026-05-08 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.58 | FDA BLA125554: OPDIVO (NIVOLUMAB) — BRISTOL MYERS SQUIBB | fda 2026-05-12 | INF_027 AI infrastructure applied to structural biology will compress drug-development timelines from approximately a decade to weeks — potentially eradicating many major diseases within 10 years. Requires localized high-speed InfiniBand networking inside the DC. Demis Hassabis | Biotech/Longevity | 38% | |
| 0.58 | FDA BLA761468: HEPCLUDEX (BULEVIRTIDE-GMOD) — GILEAD SCIENCES INC | fda 2026-05-22 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.58 | FDA ANDA077420: LAMOTRIGINE (LAMOTRIGINE) — RISING | fda 2026-05-15 | 247_041 AI-powered drugs have 85% phase 1 success vs 52% traditional Peter Diamandis | Biotech/Longevity | 55% | |
| 0.58 | FDA ANDA220043: VORICONAZOLE (VORICONAZOLE) — HAINAN POLY PHARM | fda 2026-05-29 | CMQ_035 HBM4 16-layer stack design (required for Vera Rubin) places unprecedented yield and capacity strain on global memory fabrication facilities. Jensen Huang / Morgan Stanley | Semis/Memory | 68% | |
| 0.58 | FDA ANDA077120: CARBIDOPA AND LEVODOPA (CARBIDOPA) — APOTEX INC | fda 2026-05-28 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.58 | FDA BLA761069: IMFINZI (DURVALUMAB) — ASTRAZENECA UK LTD | fda 2026-05-28 | 247_029 OpenAI Foundation's cure for Alzheimer's could spawn a trillion-dollar pharma company Alex Wissner-Gross | Biotech/Longevity | 38% | |
| 0.58 | FDA ANDA220137: TOFACITINIB CITRATE (TOFACITINIB CITRATE) — SOMERSET THERAPS LLC | fda 2026-06-03 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.58 | FDA ANDA218405: SITAGLIPTIN AND METFORMIN HYDROCHLORIDE (SITAGLIPTIN, METFORMIN HYDROCHLORIDE) — MANKIND PHARMA LTD | fda 2026-05-21 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.58 | FDA NDA220442: NDA220442 ((unspecified)) — SHIONOGI INC | fda 2026-05-29 | IND_020 Massive 'rerating' of Biotech industry — by 2026, generative biology achieves its 'De Novo' moment where an AI-designed drug candidate triggers multi-billion-dollar partnerships; AI expands Total Addressable Market (TAM) of gene editing by 100x, moving... Morgan Stanley | Biotech/Longevity | 36% | |
| 0.58 | FDA NDA220482: NDA220482 ((unspecified)) — HAISCO PHARMACEUTICAL GROUP CO LTD | fda 2026-05-29 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.58 | FDA ANDA219395: TOFACITINIB CITRATE (TOFACITINIB CITRATE) — SPECGX LLC | fda 2026-06-03 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.58 | FDA ANDA215485: RAMELTEON (RAMELTEON) — HIBROW HLTHCARE | fda 2026-06-04 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.58 | FDA BLA761458: EXDENSUR (DEPEMOKIMAB-ULAA) — GLAXOSMITHKLINE LLC | fda 2026-06-10 | INF_027 AI infrastructure applied to structural biology will compress drug-development timelines from approximately a decade to weeks — potentially eradicating many major diseases within 10 years. Requires localized high-speed InfiniBand networking inside the DC. Demis Hassabis | Biotech/Longevity | 38% | |
| 0.58 | FDA BLA761139: ENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI) — DAIICHI SANKYO | fda 2026-05-15 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.58 | FDA BLA761139: ENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI) — DAIICHI SANKYO | fda 2026-05-15 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.58 | FDA NDA021366: CRESTOR (ROSUVASTATIN CALCIUM) — ASTRAZENECA | fda 2026-04-29 | CMQ_026 NVIDIA silicon roadmap: Blackwell (2025) → Vera Rubin (2026) → Vera Rubin Ultra (2027) → Feynman (2028) — annual architectural cadence. Jensen Huang | Semis | 87% | |
| 0.58 | FDA ANDA213093: ANDA213093 ((unspecified)) — QILU PHARM CO LTD | fda 2026-04-29 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.58 | FDA ANDA076781: ONDANSETRON HYDROCHLORIDE (ONDANSETRON HYDROCHLORIDE) — HIKMA FARMACEUTICA | fda 2026-04-08 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.58 | FDA ANDA076781: ONDANSETRON HYDROCHLORIDE (ONDANSETRON HYDROCHLORIDE) — HIKMA FARMACEUTICA | fda 2026-04-08 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.58 | FDA ANDA220147: TOLVAPTAN (TOLVAPTAN) — ALKEM LABS LTD | fda 2026-04-21 | 248_030 FDA will be first government agency forced to get out of the way; government must accelerate regulation speed thousands of times. Dave Blundin | Geopolitics | 50% | |
| 0.58 | FDA ANDA207110: BOSENTAN (BOSENTAN) — WATSON LABS INC | fda 2026-04-14 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.58 | FDA ANDA213165: LENALIDOMIDE (LENALIDOMIDE) — CIPLA | fda 2026-04-27 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.58 | FDA NDA207223: DIACOMIT (STIRIPENTOL) — BIOCODEX SA | fda 2026-04-15 | TK13 Biotech/Synbio Safety Event | — | 15% | |
| 0.58 | FDA ANDA203364: MESNA (MESNA) — RISING | fda 2026-04-09 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.58 | FDA ANDA071130: HALOPERIDOL (HALOPERIDOL) — AIPING PHARM INC | fda 2026-04-08 | CMQ_009 Altman's claim of doctor-level AI diagnostic capability within 2-3 years is 'pure nonsense' — fails to account for medical communication, diagnostic uncertainty, and ethical complexity. Demis Hassabis | AI | 60% | |
| 0.58 | FDA NDA209500: CAPLYTA (LUMATEPERONE TOSYLATE) — INTRA-CELLULAR | fda 2026-04-24 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.58 | FDA ANDA091655: ESCITALOPRAM OXALATE (ESCITALOPRAM OXALATE) — MICRO LABS | fda 2026-04-22 | 245_009 Breaking plastic-degradation technology could become a supplement that breaks microplastics in the gut before absorption Peter Diamandis | Biotech/Longevity | 45% | |
| 0.58 | FDA ANDA213405: LENALIDOMIDE (LENALIDOMIDE) — TORRENT | fda 2026-04-27 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.58 | FDA ANDA210435: LENALIDOMIDE (LENALIDOMIDE) — CIPLA | fda 2026-04-27 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.58 | FDA ANDA204072: METHYLPREDNISOLONE (METHYLPREDNISOLONE) — TIANJIN TIANYAO | fda 2026-04-10 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.58 | FDA ANDA217477: ANDA217477 ((unspecified)) — HAINAN POLY PHARM. CO., LTD. | fda 2026-04-23 | FUT_019 Global market rapidly accelerates bio-industrial circumvention of fractured supply chains 2026-2031: combination of Webb agentic LAMs overseeing vast bio-reactors powered by sub-cent-per-kWh solar energy creates highly-localized completely-autonomous i... Multi-Forecaster Synthesis | Biotech/Longevity | 31% | |
| 0.58 | FDA ANDA220398: BRIMONIDINE TARTRATE (BRIMONIDINE TARTRATE) — MANKIND PHARMA | fda 2026-04-16 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.58 | FDA ANDA219494: SPIRONOLACTONE (SPIRONOLACTONE) — GRAVITI PHARMS | fda 2026-05-12 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.58 | FDA NDA021731: ELIGARD KIT (LEUPROLIDE ACETATE) — TOLMAR | fda 2026-05-06 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.58 | FDA NDA215256: WEGOVY (SEMAGLUTIDE) — NOVO | fda 2026-05-05 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.58 | FDA NDA215256: WEGOVY (SEMAGLUTIDE) — NOVO | fda 2026-05-05 | CMQ_026 NVIDIA silicon roadmap: Blackwell (2025) → Vera Rubin (2026) → Vera Rubin Ultra (2027) → Feynman (2028) — annual architectural cadence. Jensen Huang | Semis | 87% | |
| 0.58 | FDA ANDA218662: UBROGEPANT (UBROGEPANT) — ZYDUS PHARMACEUTICALS (USA) INC. | fda 2026-05-14 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.58 | FDA ANDA218662: UBROGEPANT (UBROGEPANT) — ZYDUS PHARMACEUTICALS (USA) INC. | fda 2026-05-14 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.58 | FDA ANDA078480: BRIMONIDINE TARTRATE (BRIMONIDINE TARTRATE) — APOTEX | fda 2026-05-20 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.58 | FDA ANDA217497: TRETINOIN (TRETINOIN) — AMNEAL | fda 2026-05-14 | 248_030 FDA will be first government agency forced to get out of the way; government must accelerate regulation speed thousands of times. Dave Blundin | Geopolitics | 50% | |
| 0.58 | FDA ANDA218488: EVEROLIMUS (EVEROLIMUS) — APOTEX | fda 2026-05-12 | CMQ_009 Altman's claim of doctor-level AI diagnostic capability within 2-3 years is 'pure nonsense' — fails to account for medical communication, diagnostic uncertainty, and ethical complexity. Demis Hassabis | AI | 60% | |
| 0.58 | FDA NDA213756: KOSELUGO (SELUMETINIB SULFATE) — ASTRAZENECA | fda 2026-05-26 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.58 | FDA ANDA062801: CLINDAMYCIN PHOSPHATE (CLINDAMYCIN PHOSPHATE) — ALMAJECT | fda 2026-05-28 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.58 | FDA ANDA076521: CARBIDOPA AND LEVODOPA (CARBIDOPA) — IMPAX LABS | fda 2026-05-28 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.58 | FDA NDA209091: QTERN (DAPAGLIFLOZIN) — ASTRAZENECA AB | fda 2026-06-03 | CMQ_026 NVIDIA silicon roadmap: Blackwell (2025) → Vera Rubin (2026) → Vera Rubin Ultra (2027) → Feynman (2028) — annual architectural cadence. Jensen Huang | Semis | 87% | |
| 0.58 | FDA ANDA220137: TOFACITINIB CITRATE (TOFACITINIB CITRATE) — SOMERSET THERAPS LLC | fda 2026-06-03 | 248_030 FDA will be first government agency forced to get out of the way; government must accelerate regulation speed thousands of times. Dave Blundin | Geopolitics | 50% | |
| 0.58 | FDA ANDA215332: OXCARBAZEPINE (OXCARBAZEPINE) — AUCTA | fda 2026-06-02 | CMQ_009 Altman's claim of doctor-level AI diagnostic capability within 2-3 years is 'pure nonsense' — fails to account for medical communication, diagnostic uncertainty, and ethical complexity. Demis Hassabis | AI | 60% | |
| 0.58 | FDA BLA761480: RANLUSPEC (RANIBIZUMAB-HKDZ) — LUPIN LIMITED | fda 2026-06-02 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% |